Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, August 1st. Analysts expect Conatus Pharmaceuticals to post earnings of ($0.17) per share for the quarter.

Conatus Pharmaceuticals (NASDAQ:CNAT) last released its earnings results on Thursday, May 4th. The biotechnology company reported ($0.14) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.20. The business had revenue of $7 million for the quarter, compared to the consensus estimate of $5.88 million. During the same quarter in the previous year, the firm earned ($0.35) earnings per share. On average, analysts expect Conatus Pharmaceuticals to post $-0.57 EPS for the current fiscal year and $-0.1 EPS for the next fiscal year.

Shares of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) opened at 6.19 on Tuesday. Conatus Pharmaceuticals Inc. has a 52 week low of $1.45 and a 52 week high of $9.40. The company’s market capitalization is $161.99 million. The company has a 50-day moving average price of $5.69 and a 200-day moving average price of $5.57.

Several brokerages have issued reports on CNAT. Zacks Investment Research raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. Aegis reissued a “buy” rating and issued a $11.00 target price on shares of Conatus Pharmaceuticals in a research report on Monday, May 15th. ValuEngine raised Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, May 24th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Conatus Pharmaceuticals in a research report on Thursday, June 29th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $13.25.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/07/25/conatus-pharmaceuticals-inc-cnat-set-to-announce-earnings-on-tuesday.html.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Earnings History for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.